Fresh Tracks Therapeutics, Inc. – NASDAQ:FRTX

Fresh Tracks Therapeutics stock price today

$0.8
+0.06
+8.11%
Financial Health
0
1
2
3
4
5
6
7
8
9

Fresh Tracks Therapeutics stock price monthly change

-22.11%
month

Fresh Tracks Therapeutics stock price quarterly change

-22.11%
quarter

Fresh Tracks Therapeutics stock price yearly change

-8.64%
year

Fresh Tracks Therapeutics key metrics

Market Cap
4.43M
Enterprise value
N/A
P/E
-0.08
EV/Sales
-0.61
EV/EBITDA
0.21
Price/Sales
0.14
Price/Book
0.22
PEG ratio
N/A
EPS
-1.40
Revenue
N/A
EBITDA
-5.77M
Income
-5.63M
Revenue Q/Q
-100%
Revenue Y/Y
15.31%
Profit margin
-278.93%
Oper. margin
-285.45%
Gross margin
4.28%
EBIT margin
-285.45%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Fresh Tracks Therapeutics stock price history

Fresh Tracks Therapeutics stock forecast

Fresh Tracks Therapeutics financial statements

Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX): Profit margin
Mar 2023 9K -4.21M -46822.22%
Jun 2023 53K -2.28M -4309.43%
Sep 2023 7.94M 2.10M 26.49%
Dec 2023 0 -1.23M
Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX): Analyst Estimates
2025 16.8M -4.13M -24.64%
  • Analysts Price target

  • Financials & Ratios estimates

Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX): Debt to assets
Mar 2023 11967000 2.10M 17.56%
Jun 2023 9842000 1.85M 18.8%
Sep 2023 13057000 2.10M 16.14%
Dec 2023 11586000 1.65M 14.29%
Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX): Cash Flow
Mar 2023 -4.48M 0 6.56M
Jun 2023 -1.81M 0 0
Sep 2023 3.08M 0 -10K
Dec 2023 -1.12M 0 -28K

Fresh Tracks Therapeutics alternative data

Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX): Employee count
Aug 2023 13
Sep 2023 13
Oct 2023 13
Nov 2023 13
Dec 2023 13
Jan 2024 13
Feb 2024 13
Mar 2024 4
Apr 2024 4
May 2024 4
Jun 2024 4
Jul 2024 4

Fresh Tracks Therapeutics other data

1.89% -3.35%
of FRTX is owned by hedge funds
53.14K -99.18K
shares is hold by hedge funds

Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX): Insider trades (number of shares)
Period Buy Sel
Dec 2023 77000 110
Jan 2024 150000 0
Feb 2024 97513 0
Mar 2024 70846 0
Apr 2024 42448 0
May 2024 273105 0
Jun 2024 405500 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
EXPLORATION CAPITAL, LLC 10 percent owner
Common Stock 86,185 $0.94 $81,014
Purchase
EXPLORATION CAPITAL, LLC 10 percent owner
Common Stock 319,315 $0.94 $300,156
Purchase
EXPLORATION CAPITAL, LLC 10 percent owner
Common Stock 516 $0.89 $459
Purchase
EXPLORATION CAPITAL, LLC 10 percent owner
Common Stock 9,838 $0.92 $9,051
Purchase
EXPLORATION CAPITAL, LLC 10 percent owner
Common Stock 80 $0.87 $70
Purchase
EXPLORATION CAPITAL, LLC 10 percent owner
Common Stock 15,627 $0.91 $14,221
Purchase
EXPLORATION CAPITAL, LLC 10 percent owner
Common Stock 383 $0.89 $341
Purchase
EXPLORATION CAPITAL, LLC 10 percent owner
Common Stock 6,879 $0.91 $6,260
Purchase
EXPLORATION CAPITAL, LLC 10 percent owner
Common Stock 797 $0.91 $725
Purchase
EXPLORATION CAPITAL, LLC 10 percent owner
Common Stock 73,768 $0.92 $67,867
Friday, 6 December 2024
prnewswire.com
Monday, 17 June 2024
globenewswire.com
Wednesday, 14 February 2024
globenewswire.com
Wednesday, 27 December 2023
globenewswire.com
Tuesday, 19 December 2023
globenewswire.com
Monday, 18 December 2023
globenewswire.com
Friday, 15 December 2023
globenewswire.com
Friday, 1 December 2023
globenewswire.com
Friday, 17 November 2023
globenewswire.com
Monday, 13 November 2023
globenewswire.com
Tuesday, 19 September 2023
globenewswire.com
Friday, 25 August 2023
InvestorPlace
  • What's the price of Fresh Tracks Therapeutics stock today?

    One share of Fresh Tracks Therapeutics stock can currently be purchased for approximately $0.8.

  • When is Fresh Tracks Therapeutics's next earnings date?

    Unfortunately, Fresh Tracks Therapeutics's (FRTX) next earnings date is currently unknown.

  • Does Fresh Tracks Therapeutics pay dividends?

    No, Fresh Tracks Therapeutics does not pay dividends.

  • How much money does Fresh Tracks Therapeutics make?

    Fresh Tracks Therapeutics has a market capitalization of 4.43M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 15.31% to 8.01M US dollars.

  • What is Fresh Tracks Therapeutics's stock symbol?

    Fresh Tracks Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "FRTX".

  • What is Fresh Tracks Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Fresh Tracks Therapeutics?

    Shares of Fresh Tracks Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Fresh Tracks Therapeutics have?

    As Jul 2024, Fresh Tracks Therapeutics employs 4 workers.

  • When Fresh Tracks Therapeutics went public?

    Fresh Tracks Therapeutics, Inc. is publicly traded company for more then 32 years since IPO on 10 Mar 1993.

  • What is Fresh Tracks Therapeutics's official website?

    The official website for Fresh Tracks Therapeutics is frtx.com.

  • Where are Fresh Tracks Therapeutics's headquarters?

    Fresh Tracks Therapeutics is headquartered at 5777 Central Avenue, Boulder, CO.

  • How can i contact Fresh Tracks Therapeutics?

    Fresh Tracks Therapeutics's mailing address is 5777 Central Avenue, Boulder, CO and company can be reached via phone at +7 205054755.

Fresh Tracks Therapeutics company profile:

Fresh Tracks Therapeutics, Inc.

frtx.com
Exchange:

NASDAQ

Full time employees:

4

Industry:

Biotechnology

Sector:

Healthcare

Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

5777 Central Avenue
Boulder, CO 80301

CIK: 0000819050
ISIN: US10802T2042
: